Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of oral microencapsulated grass pollen extract for grass pollen allergic rhinoconjunctivitis
2007-003345-33Phase 2Terminated
- Sponsor
- Curalogic
- Start
- Aug 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of microencapsulated grass pollen extract in allergic rhinoconjunctivitis (ARC) and seasonal allergic rhinitis (SAR) (3 arms), sponsored by Curalogic. Primary endpoint: Average daily Total Symptom Score during peak grass pollen season. Started Aug 2007; status: terminated.
02
Drugs
microencapsulated grass pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2007-003345-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003345-33.